GlassScriptPhysician profile
Jacqueline E Hayes
NPI 1134275662
$4,949.80
in general payments reported to CMS, 2019-2025
38 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.09 · 2020: $15.79 · 2022: $989 · 2023: $1,964 · 2024: $1,638 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,930.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.93 | 2022-2025 | |
| Pfizer INC. | $608.92 | 2022-2025 | |
| Novo Nordisk INC | $538.56 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $414.66 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $299.93 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.20 | 2022-2025 | Trintellix |
| Glaxosmithkline, LLC. | $205.98 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $195.20 | 2022-2023 | Belsomra, Steglatro, Gardasil 9 |
| Abbott Laboratories | $192.38 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $174.12 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $149.68 | 2022-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $148.76 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $106.35 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $89.49 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $73.78 | 2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.